Amphastar P

Amphastar P

AMPH · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

29.37USD+0.50 (+1.73%)

Price History

Full chart

Market Stats

Previous Close28.87
Open29.05
Day Range28.84 – 29.73
52-Week Range16.65 – 29.52
Volume380.76K
Market Cap1.12B
P/E (TTM)14.76
Forward P/E0.00
EPS1.78
Dividend Yield0.00%
Beta0.92
50-Day Avg21.68
200-Day Avg22.34

About

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEODr. Yongfeng Zhang Ph.D.
  • Employees1.98K
  • Headquarters11570 6th Street, Rancho Cucamonga, CA, United States, 91730, USA
  • Websitehttps://www.amphastar.com

Leadership

  • Dr. Ziping Luo Ph.D.Chairman of the Board, Chief Scientist & COO · b. 1950
  • Dr. Yongfeng Zhang Ph.D.Co-Founder, President, CEO, Chief Scientific Officer & Director · b. 1947
  • Mr. William J. Peters M.B.A.CFO, Executive VP of Finance, Treasurer & Director · b. 1968
  • Mr. Jacob Liawatidewi M.B.A.Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director · b. 1974
  • Mr. Rong Zhou M.S.Senior EVP of Production & EVP of Scientific Affairs · b. 1959
  • Mr. Dan Dischner M.B.A.Senior Vice President of Human Resources & Corporate Communication
  • Tony Marrs M.B.A., M.P.H., M.S.Executive VP of Regulatory Affairs & Clinical Operations

Financials

Income Statement

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue118.36M204.32M229.68M210.46M251.52M255.16M240.18M294.67M322.36M349.85M437.77M498.99M644.39M731.97M719.89M
Growth (%)-+72.63%+12.41%-8.37%+19.51%+1.45%-5.87%+22.69%+9.40%+8.53%+25.13%+13.98%+29.14%+13.59%-1.65%
Cost of Revenue90.25M114.02M142.72M159.21M174.17M150.98M149.38M187.68M190.43M206.51M238.03M250.13M293.27M358.11M363.83M
Gross Profit28.10M90.30M86.96M51.26M77.35M104.19M90.80M106.98M131.92M143.34M199.74M248.86M351.12M373.86M356.06M
Gross Margin23.75%44.20%37.86%24.35%30.75%40.83%37.80%36.31%40.92%40.97%45.63%49.87%54.49%51.08%49.46%
Operating Expense61.65M64.91M69.47M69.24M84.25M88.50M91.69M115.61M131.96M132.39M129.85M141.36M154.13M168.44M215.65M
Operating Income-33.55M25.40M17.49M-17.98M-6.90M15.69M-895.00K-8.62M-39.00K10.95M69.89M107.50M196.99M205.42M140.40M
Operating Margin-28.34%12.43%7.61%-8.54%-2.74%6.15%-0.37%-2.93%-0.01%3.13%15.96%21.54%30.57%28.06%19.50%
EBITDA-20.15M38.16M30.69M-3.09M3.88M30.26M11.90M7.89M21.08M30.19M111.56M146.16M240.29M277.31M212.31M
EBITDA Margin-17.03%18.68%13.36%-1.47%1.54%11.86%4.95%2.68%6.54%8.63%25.48%29.29%37.29%37.89%29.49%
Net Income7.75M18.09M11.86M-10.70M-2.79M10.53M4.51M-5.74M48.94M1.40M62.12M91.39M137.54M159.52M98.09M
Net Income Margin6.55%8.86%5.16%-5.08%-1.11%4.13%1.88%-1.95%15.18%0.40%14.19%18.31%21.34%21.79%13.63%
R&D31.05M31.16M33.02M28.43M37.06M41.20M43.41M57.56M68.85M67.23M60.93M74.77M73.74M73.91M85.84M
R&D as % of Total Revenue26.23%15.25%14.38%13.51%14.74%16.15%18.08%19.54%21.36%19.22%13.92%14.98%11.44%10.10%11.92%
Interest Expense584.00K784.00K958.00K609.00K987.00K1.02M826.00K243.00K119.00K374.00K885.00K1.85M27.16M30.34M25.48M
Interest Expense % of Total Revenue0.49%0.38%0.42%0.29%0.39%0.40%0.34%0.08%0.04%0.11%0.20%0.37%4.21%4.15%3.54%

Balance Sheet

Currency: USD2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets--317.48M338.75M389.37M390.14M427.74M454.67M513.56M586.97M631.24M671.53M741.99M1.51B1.58B1.63B
Total Liabilities--84.04M87.20M107.51M94.63M98.48M117.34M149.20M159.44M182.51M226.01M213.33M873.49M845.17M840.49M
Total Equity--233.44M251.54M281.86M295.51M329.25M337.33M332.44M381.37M402.31M445.52M528.66M639.42M732.30M788.80M
Cash--50.21M53.59M67.83M66.07M72.35M65.59M86.34M75.55M92.64M126.35M156.10M144.30M151.61M170.18M
Total Debt--38.00M32.17M43.70M41.10M37.72M47.16M50.21M66.63M67.27M104.66M102.58M623.64M650.55M656.00M
Net Debt---12.21M-21.41M-24.13M-24.98M-34.63M-18.44M-36.12M-8.93M-25.37M-21.69M-53.52M479.35M498.94M485.82M

Cash Flow

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow19.10M-1.65M31.04M21.05M10.68M38.56M39.21M38.19M41.76M57.27M97.99M89.18M183.50M213.39M156.12M
Investing Cash Flow-10.54M-25.11M-18.30M-39.77M-16.93M-39.50M-38.76M-42.18M-50.53M-36.41M-28.67M-32.78M-649.12M-124.93M-70.33M
Financing Cash Flow-8.58M23.24M-9.37M32.12M2.24M7.14M-7.72M25.01M-3.78M-2.25M-37.02M-26.44M454.09M-80.95M-67.42M
Capital Expenditure10.72M25.25M18.30M20.50M16.05M21.38M35.10M46.81M41.55M33.85M27.46M24.03M38.17M41.04M34.88M
Free Cash Flow8.38M-26.89M12.74M553.00K-5.37M17.18M4.11M-8.62M207.00K23.41M70.54M65.15M145.34M172.34M121.23M
Dividends Paid---52.08M20.29M10.20M020.31M-23.16M15.93M15.66M454.09M--
FCF to OCF43.87%1630.00%41.04%2.63%-50.24%44.55%10.48%-22.56%0.50%40.88%71.98%73.05%79.20%80.77%77.66%
Dividend Paid to FCF---9417.00%-378.07%59.37%0.00%-235.72%-98.95%22.58%24.03%312.44%--

Earnings

Report DateAug 12, 2014Nov 12, 2014Mar 24, 2015May 13, 2015Aug 12, 2015Nov 12, 2015Mar 14, 2016May 9, 2016Aug 8, 2016Nov 8, 2016Mar 13, 2017May 8, 2017Aug 9, 2017Nov 8, 2017Mar 12, 2018May 9, 2018Aug 8, 2018Nov 8, 2018Mar 12, 2019May 9, 2019Aug 7, 2019Nov 7, 2019Mar 12, 2020May 7, 2020Aug 6, 2020Nov 6, 2020Mar 15, 2021May 6, 2021Aug 9, 2021Nov 8, 2021Mar 10, 2022May 9, 2022Aug 8, 2022Nov 7, 2022Feb 28, 2023May 9, 2023Aug 8, 2023Nov 8, 2023Feb 28, 2024May 8, 2024Aug 7, 2024Nov 6, 2024Feb 26, 2025May 7, 2025Aug 7, 2025Nov 6, 2025Feb 26, 2026May 7, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate-0.09-0.09-0.06-0.02-0.13-0.08-0.04-0.030.040.08-0.010.080.070.03-0.020.080.080.110.110.050.050.070.080.090.140.140.140.180.210.230.360.360.350.390.410.500.560.690.910.790.750.980.940.690.640.830.890.710.510.84
EPS Actual0.02-0.07-0.03-0.01-0.09-0.010.190.120.230.140.010.090.110.070.10-0.050.030.120.130.100.080.100.070.170.160.150.160.270.210.460.420.470.390.380.730.620.651.150.881.040.940.960.920.740.750.930.610.420.80-
Surprise122.22%22.22%50.00%50.00%30.77%87.50%575.00%500.00%475.00%75.00%200.00%12.50%57.14%133.33%600.00%-162.50%-62.50%9.09%18.18%100.00%60.00%42.86%-12.50%88.89%14.29%7.14%14.29%50.00%0.00%100.00%16.67%30.56%11.43%-2.56%78.05%24.00%16.07%66.67%-3.30%31.65%25.33%-2.04%-1.95%7.25%17.19%12.05%-31.46%-40.85%56.86%-
TimingAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap1.12B
Enterprise Value1.46B
Trailing P/E14.76
Forward P/E0.00
PEG Ratio2.77
Price / Sales1.53
Price / Book1.38
EPS1.78
Book Value18.06
Revenue (TTM)730.02M
Gross Profit (TTM)348.11M
EBITDA194.51M
Profit Margin10.76%
Operating Margin21.60%
Return on Equity10.30%
Return on Assets5.11%
Shares Outstanding42.54M
Shares Float31.29M
Beta0.92
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 6 analystsTarget 22.50
  • Strong Buy
    2
  • Hold
    4

Ownership Breakdown

Institutions
69.59%
Insiders
30.81%
Retail / Other
0.00%

Top Institutional Holders

  • BlackRock Inc
    5.42M12.74%
  • Dimensional Fund Advisors, Inc.
    2.31M5.42%
  • State Street Corp
    1.61M3.78%
  • Vanguard Capital Management, LLC
    1.54M3.63%
  • Fuller & Thaler Asset Management Inc
    1.40M3.28%
  • American Century Companies Inc
    1.18M2.77%
  • Marshall Wace Asset Management Ltd
    1.03M2.41%
  • Geode Capital Management, LLC
    976.65K2.30%
  • TD Global Investment Solutions – TD Epoch
    898.89K2.11%
  • D. E. Shaw & Co LP
    887.05K2.09%
  • Vanguard Portfolio Management, LLC
    787.82K1.85%
  • LSV Asset Management
    642.01K1.51%
  • Amvescap Plc.
    604.77K1.42%

Top Fund Holders

  • iShares Core S&P Small-Cap ETF
    2.07M4.86%
  • Avantis US Small Cap Value ETF
    1.14M2.68%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.06M2.48%
  • TD U.S. Capital Reinvestment I
    981.53K2.31%
  • FullerThaler Behavioral Sm-Cp Eq R6
    902.74K2.12%
  • iShares Russell 2000 ETF
    835.03K1.96%
  • DFA US Small Cap Value I
    596.08K1.40%